Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
34 hedge funds and large institutions have $29.4M invested in Genocea Biosciences, Inc. in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 9 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% less funds holding
Funds holding: 37 → 34 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
26% less capital invested
Capital invested by funds: $39.8M → $29.4M (-$10.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$181K |
| 2 |
BlackRock
New York
|
+$161K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$145K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$119K |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$173K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$100K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$36.2K |
| 4 |
D.E. Shaw & Co
New York
|
-$31K |
| 5 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
-$15K |
GNCA Hedge Fund Activity: Q4 2019 in Review
34 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2019, worth a combined $29.4M — down 26% from $39.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GNCA and 7 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $181K. The largest seller was Millennium Management, cutting an estimated $173K.
- 34 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2019, down from 37 in Q3 2019.
- Funds reported $29.4M of Genocea Biosciences, Inc. stock for Q4 2019, down 26% quarter-over-quarter.
- 7 funds opened new Genocea Biosciences, Inc. positions in Q4 2019 and 9 closed out, a net change of -2 holders.
- The largest Genocea Biosciences, Inc. buyer in Q4 2019 was Renaissance Technologies, an estimated $181K added.
- The largest Genocea Biosciences, Inc. seller in Q4 2019 was Millennium Management, an estimated $173K sold.
Based on aggregated 13F filings for Q4 2019.